ERBB2 and breast cancer: However, it should be noted that BC patients with LVD in the overall study population underwent a greater number of Cardio-Oncologic evaluation as compared to those without LVD (Figure 2), while this result was not found in the anti-HER2 subgroup, likely due to the regular echocardiographic monitoring these patients undergo.